EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort

Background: Beyond programmed death ligand 1 (PD-L1), no other biomarkers for immunotherapy are used in daily practice. We previously created EPSILoN (Eastern Cooperative Oncology Group performance status (ECOG PS), smoking, liver metastases, lactate dehydrogenase (LDH), neutrophil-to-lymphocyte rat...

Descripción completa

Detalles Bibliográficos
Autores principales: Prelaj, Arsela, Ferrara, Roberto, Rebuzzi, Sara Elena, Proto, Claudia, Signorelli, Diego, Galli, Giulia, De Toma, Alessandro, Randon, Giovanni, Pagani, Filippo, Viscardi, Giuseppe, Brambilla, Marta, Trevisan, Benedetta, Ganzinelli, Monica, Martinetti, Antonia, Gallucci, Rosaria, Di Mauro, Rosa Maria, Molino, Giuliano, Zilembo, Nicoletta, Torri, Valter, de Braud, Filippo Maria, Garassino, Marina Chiara, Lo Russo, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966664/
https://www.ncbi.nlm.nih.gov/pubmed/31817541
http://dx.doi.org/10.3390/cancers11121954

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966664/
https://www.ncbi.nlm.nih.gov/pubmed/31817541
http://dx.doi.org/10.3390/cancers11121954

Ejemplares similares